FreeTheAI

Oncopeptides Plans SEK 100M Share Issue for Glioblastoma Program

MixedMedium impact
ONCOSEK 2.32 −4.20%

Oncopeptides AB (OMXSTO:ONCO) plans to raise approximately SEK 100 million through a directed share issue conducted via an accelerated bookbuilding procedure. The biotech company's stock dropped 4.12% to 2.326 SEK following the announcement.

The capital raise aims to fund development activities for the company's glioblastoma program. Oncopeptides held SEK 117 million in cash as of September 30, making the new funding a key step to support its ongoing research and development. HealthCap, the firm's largest shareholder, plans to subscribe for SEK 10 million in the offer. However, issuing new equity introduces dilution risk for existing shareholders until pricing and final allocation are established.

The accelerated bookbuild is expected to close prior to the start of trading on October 14, 2026, when final share pricing and issue size will be set. The transaction includes a 90-day lock-up period for the company, limiting additional near-term equity offerings.

Key points

  • Oncopeptides intends to raise about SEK 100 million through a directed share issue.
  • Proceeds will be used to fund activities for the company's glioblastoma program.
  • Largest shareholder HealthCap plans to subscribe for SEK 10 million in the offering.
  • The accelerated bookbuilding process is scheduled to conclude before trading on October 14, 2026.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Why is Oncopeptides raising SEK 100 million?

Oncopeptides is raising capital through a directed share issue to fund development activities for its glioblastoma research program.

When will the Oncopeptides share issue pricing be finalized?

Pricing and final allocation will be determined after the accelerated bookbuilding process closes, expected before trading begins on October 14, 2026.

How much cash did Oncopeptides hold prior to the share issue?

Oncopeptides had SEK 117 million in cash as of September 30.